Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The study included an initial dataset of 4,200 patients. In total, 4,196 of these participants were eligible—431 of which had EGFR mutations.
Results showed women had significantly greater (P <0.0001) odds of EGFR mutations compared to males (OR: 1.85; 95% C: 1.48, 2.32).
A similar trend was observed for never-smokers versus smokers (OR, 3.64; 95% CI: 2.91, 4.56), and patients with adenocarcinoma versus other histologic subtypes (OR, 2.94; 95% CI: 2.17, 4.08).
Furthermore, EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutation–positive non-small cell lung cancer (NSCLC) and combination chemotherapy in EGFR mutation–negative NSCLC were determined to be the most commonly prescribed first-line systemic treatments (56.6% and 78.5%, respectively).
↵* Corresponding Author: W. Schuette, Hospital Martha-Maria, Roentgenstr. 1, Halle-Dölau, 06120 Halle, Germany. Phone: 49-345-559-1440; Fax: 49-345-680-0376; E-mail: Wolfgang.Schuette{at}Martha-Maria.de W. Schuette and P. Schirmacher contributed equally to this article. Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in advanced non-small cell lung cancer (NSCLC).
READ FULL ARTICLE
From cebp.aacrjournals.org
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.